AHA 2017: Applying PCSK9 Inhibitors to Improve Outcomes and the Overall Quality of Life for Patients with Dyslipidemia

This Elsevier Conference Reporter will cover data presented at the American Heart Association (AHA) Scientific Session 2017 held in Anaheim, CA. The expert faculty will discuss the role of PCSK9 inhibitors for the treatment of dyslipidemia including achieving LDL-C goals, cardiovascular risk reduction and managing special patient populations. Current and emerging clinical trial data of PCSK9 inhibitors will be analyzed. The faculty will discuss different approaches of how to implement newer therapies into individualized treatment plans. Upon completing this activity, clinicians will gain a better understanding of treatment options to provide better outcomes for patients with dyslipidemia.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of cardiologists, primary care physicians, and other healthcare professionals who care for patients with dyslipidemia

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

  1. Discuss the role of PCSK9 inhibitors for the treatment of dyslipidemia, including cardiovascular risk reduction, achieving LDL-C goals and managing special patient populations.
  2. Analyze clinical trial data of current and emerging PCSK9 inhibitors for the treatment of dyslipidemia, as presented at AHA 2017.
  3. Incorporate newer therapies into individualized treatment plans to improve outcomes for patients with dyslipidemia.

FACULTY

Christopher P. Cannon, MD
Professor of Medicine
Harvard Medical School
Executive Director of Cardiometabolic Trials
Baim Institute for Clinical Research
Cardiovascular Division
Brigham and Women’s Hospital
Boston, Massachusetts

Michael J. Blaha, MD, MPH
Associate Professor of Medicine
Director of Clinical Research
Ciccarone Center for the Prevention of Heart Disease
Johns Hopkins College of Medicine
Baltimore, Maryland

Marc S. Sabatine, MD
Chairman, TIMI Study Group Senior Physician
Division of Cardiovascular Medicine
BWH Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Stephen D. Wiviott, MD
Cardiovascular Division
Brigham and Women's Hospital
Associate Professor of Medicine
Harvard Medical School
Senior Investigator, TIMI Study Group
Boston, Massachusetts

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
Christopher P. Cannon, MD

Consultant/Advisor: Alnylam Pharmaceuticals, Inc.; Amgen Inc.; Amarin Corporation; Arisaph Pharmaceuticals, Inc.; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Company; Eisai Co., Ltd.; GlaxoSmithKline Plc; Kowa; LipoMedix; Merck & Co., Inc.; Pfizer Inc.; Regeneron; Sanofi; Takeda Pharmaceuticals U.S.A., Inc.

Grant/Research Support: Amgen Inc.; Arisaph Pharmaceuticals, Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo Company Limited; Janssen Global Services, LLC; Merck & Co., Inc.; Takeda Pharmaceuticals U.S.A., Inc.

Michael J. Blaha MD

Consultant/Advisor: Amgen Inc; MedImmune; Ferring Pharmaceuticals

Grant/Research Support: Aetna Foundation; Amgen Inc.; American Heart Association, Inc.

Marc S. Sabatine, MD

Consultant/Advisor: Amgen Inc.; Bristol-Myers Squibb Company; CVS/caremark; Esperion; Intarcia Therapeutics, Inc.; Janssen Global Services, LLC.; MedImmune; Merck & Co., Inc.; Novartis Pharmaceutical Corporation

Grant/Research Support: Amgen Inc.; AstraZeneca; Daiichi-Sankyo Company Limited; Eisai Co., Ltd.; GlaxoSmithKline Plc; Intarcia Therapeutics, Inc.; Janssen Global Services, LLC.; The Medicines Company; MedImmune; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Poxel PA; Takeda Pharmaceuticals U.S.A., Inc.

Stephen D. Wiviott, MD

Consultant/Advisor: Arena Pharmaceuticals, Inc.; AstraZeneca; Aegerion Pharmaceuticals; Allergan; Angel Medical Systems, Inc.; Boehringer Ingelheim; Boston Clinical Research Institute, LLC.; Bristol-Myers Squibb Company; Daiichi Sankyo Company Limited; Eisai Co., Ltd.; Eli Lilly and Company; ICON plc.; Janssen Global Services, LLC; Lexicon Pharmaceuticals, Inc.; Merk & Co., Inc.; St. Jude Medical, LLC.; Xoma

Grant/Research Support: Amgen Inc; Arena Pharmaceuticals, Inc.; AstraZeneca; Bristol-Myers Squibb Company; Daiichi Sankyo Company Limited; Eisai Co., Ltd.; Eli Lilly and Company; Janssen Global Services, LLC; Merck & Co., Inc.; sanofi-aventis U.S. LLC.

Non-faculty: Sandy Breslow; Alison Kemp; Bernard M. Abrams, MD; Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski and Chelsey Benedek hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Amgen Inc.

Provider Information

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.

Credit Designation Statement

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
12/20/2017
Course expires: 
12/19/2018
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician

Accreditation Period

Course opens: 
12/20/2017
Course expires: 
12/19/2018
Please login or register to take this course.